Zika PRVABC59 Strips

Zika Virus (ZIKV) was first discovered from a Rhesus Monkey in the Zika forest of Uganda in 1947. More recently, there have been outbreaks in Southeast Asia, the Pacific Islands and the Americas. ZIKV has caused a global health concern since infections have been linked to cases of Guillain-Barré syndrome and birth defects. There are two lineages of the virus: The African, and the Asian lineage. Phylogenetic studies indicate that the virus spreading in the Americas is most closely related to the Asian lineage. ZIKV is a member of the virus family flaviviridae and the genus flavivirus transmitted by mosquitoes. It is related to the dengue, yellow fever, Japanese encephalitis, and West Nile viruses. The virus produces 3 structural (capsid [C], premembrane [prM], envelope [E]) and 7 non-structural proteins (including NS1). Studies from other flaviviruses demonstrate an immune response primarily targets the prM, E and the secreted NS1 proteins.

Zeptometrix | 0801021 | Zika PRVABC59 Strips Datasheet

PRODUCT CHARACTERISTICS:

Composition: Derived from electroblotting detergent disrupted ZIKV infected cells separated by SDS polyacrylamide gel electrophoresis under non-reducing conditions to preserve conformational epitopes. Strips contain a control band of goat anti-human IgG that reacts when human or non-human primate IgG antibodies are present to control for sample addition. Mouse IgG antibodies will also yield a weak reaction to the control band.
Source: ZIKV strain PRVABC59 (Asian Lineage: Accession No. KU501215) from infected Vero cells (kidney epithelial, African Green Monkey).
Specificity: Reactive to Zika antibodies. Likely cross-reactive to other Flavivirus antibodies.
CONTENTS: One tube of 10 nitrocellulose strips.
STORAGE: Store at 2-8ºC. Keep tightly capped. Allow tube to reach room temperature before opening.

RECOMMENDED USAGE: Test the reactivity of antibody sera at a 1:100-10,000 dilution. Test reactivity of monoclonal antibodies from 0.5-50 µg/mL.

Nitrocellulose strips were incubated with a 1:100 dilution of a strongly reactive human specimen positive for Zika antibodies. An alkaline phosphatase-conjugated goat anti-human IgG was used as a secondary antibody and NBT/BCIP as substrate solution to develop the signal.

REFERENCES: Pierson and Graham (2016), Zika Virus: Immunity and Vaccine Development. Cell 167, 625-631